Because the expression of specific survivin isoforms in breast cancer tissue correlates with poorer outcomes [16,17] and survivin in non-tumor tissue (e.g., reactive normal breast tissue) may provoke unwanted autoimmune effects, we sought to characterize the complete expression profile of survivin in tumor and normal autologous tissues. The gene discussed is BIRC5; the disease is breast carcinoma.